EUDAMED Status Update 2021
The development and deployment of EUDAMED is progressing. Following the implementation plan and getting familiar with the information stored in the database's modules is crucial for economic operators compliance in the EU market.
Liliana Teles

Liliana Teles

Regulatory Affairs Manager

EUDAMED is the IT system developed by the European Commission to implement Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnosis medical devices.

The system database is multipurpose, interoperable and structured around 6 interconnected modules and a public website:

  • Actor Registration – ACT
  • Unique Device Identification/Devices Registration – UDI
  • Notified Bodies and Certificates – CRF
  • Clinical Investigations and Performance Studies – CIPS
  • Vigilance and Post-Market Surveillance – VGL
  • Market Surveillance – MSU

What is stored in the EUDAMED?

Module ACT – Actor Registration

This module allows actors – manufacturers, system & procedure pack producers, importers and EU authorised representatives – to register. When an economic operator has submitted its actor registration request, the selected relevant national competent authority issues the Actor ID/ Single Registration Number (SRN) generated by EUDAMED, after approving the registration request. Actors are clearly identified through the SRN. After registration and verification of the data provided, the actors will have access to EUDAMED. 

Since the 1st December 2020 all actor information registered in EUDAMED are publicly available.

At the moment the European Commission is not in a position to require the use of the Actor registration module until EUDAMED is fully functional according to the Medical Device Regulation and additional national requirements on registrations can therefore not be excluded.

Module UDI – Unique Device Identification/Devices Registration

The UDI module contains all device-specific information. The UDI data is divided into BASIC UDI-DI and the UDI-DI. The BASIC UDI-DI serves to map all common properties of a product group. The UDI-DI contains only the product-specific information. 

As an economic operator, you are responsible for managing all UDI attributes in your own company and transferring the data to EUDAMED.

Information on the registered Basic UDI-DI, UDI-DI and Device are publicly available.

Module CRF – Notified Bodies and Certificates

Certificates issued by Notified Bodies on Quality Management System and Conformity Assessment in accordance with MDR 2017/745 and IVDR 2017/746 are stored in this module. The module is used to enable communication between the Notified Bodies and to monitor the status of the consultation procedures for clinical evaluations.

Public access will be granted to the registration of certificates of conformity, their scope and validity period, as well as the reports of the Notified Bodies on the SCCP.

Module CIPS – Clinical Investigations and Performance Studies 

This module will be used to manage clinical investigation and performance evaluation data. Besides, applications for clinical performance studies and trials can be submitted, as well as clinical follow-ups and post-market product changes and reports.

Clinical Investigation Registration, Clinical Investigation Results Reporting and Publication are accessible to the public. Clinical Investigation Application Documents will potentially be accessible by the public.

Module VGL – Vigilance and Post-Market Surveillance 

Several reports can be submitted via the Vigilance Module: Periodic Safety Update Report (PSUR; Periodic Summary Reports (PSR) and Reporting of Serious Incidents and Field Safety Corrective Actions (FSCAs) and Field Safety Notices (FSNs). FSCAs are automatically distributed to the appropriate authorities after they are reported in the Vigilance Module. 

Partial public access for manufacturer incident reports and Field Safety Notices.

Module MSUMarket Surveillance

This module is designed to facilitate cooperation and coordination between competent authorities of EU Member States.

Public may access the summary of the results of the reviews and assessments of the market surveillance activities.

What is the state of play of the implementation of EUDAMED?

The development and deployment of EUDAMED is progressing:

The module on Actor Registration (first module) went live in December 2020.

The module on UDI/Device Registration (second module) and the module on Notified Bodies and Certificates (third module) are available since October 2021 except for the mechanism for scrutiny and the clinical evaluation consultation procedure (CECP) functionalities. 

The remaining three modules – Clinical Investigations and Performance Studies, Vigilance and Post-Market Surveillance and Market Surveillance – as well as the mechanism for scrutiny and the CECP will be launched when EUDAMED is fully operational in May 2022.

References: European Commission – Medical Devices – EUDAMED. Available at: https://ec.europa.eu/health/md_eudamed/overview_en

further
reading

cosmetic products

New Formaldehyde Threshold in Cosmetic Products

The European Commission has issued a draft regulation to amend the preamble of Annex V regarding the threshold for labelling formaldehyde releasers. This amendment results from a scientific advice published by the SCCS concluding that the current threshold does not sufficiently protect consumers sensitized to formaldehyde.

Read More »
cosmetic products

New Restriction on the Use of Benzophenone-3 in Cosmetics

Benzophenone-3 was part of a priority list of potential endocrine disruptors established by the European Commission in 2019. The SCCS was asked to assess the safety of this ingredient and the European Cosmetics Regulation will be amended in accordance with the SCCS assessment conclusions.

Read More »
endocrine disruptors
cosmetic products

European Commission Calls for Data on Ingredients with Potential Endocrine-Disrupting Properties

Substances classified as endocrine disruptors are compounds that can alter the functioning of the endocrine system and negatively affect the health of humans and animals. In 2019, the European Commission set out two lists of ingredients suspected of having endocrine disrupting properties. More recently, the Commission has published a call for data for 10 ingredients that were included in the low priority group (Group B) for the SCCS to be able to assess their safety.

Read More »
cosmetic products

SCCS Preliminary Opinion on Prostaglandins and Prostaglandin-analogues

Following the mandate from the European Commission, the Scientific Committee on Consumer Safety (SCCS) has published a preliminary opinion on Prostaglandins and Prostaglandin-analogues used in cosmetic products. This preliminary opinion is open for comments and the deadline was set for 23 november 2021.

Read More »
cosmetic products

SCCS Preliminary Opinion on Butylated Hydroxytoluene (BHT)

Following the mandate from the European Commission, the Scientific Committee on Consumer Safety (SCCS) has published a preliminary opinion on Butylated Hydroxytoluene (BHT). This preliminary opinion is open for comments and the deadline was set for 23 november 2021.

Read More »
cosmetic products

EU Prohibition of Zinc Pyrithione in Cosmetic Products

Zinc Pyrithione has been used for more than 60 years as an anti-dandruff agent in cosmetic products. Last month, the European Commission published the Commission Regulation (EU) 2021/1092, which includes this ingredient in Annex II. From March 2022 onwards, Zinc Pyrithione will be prohibited in cosmetic products.

Read More »
medical devices

EUDAMED Status Update 2021

The development and deployment of EUDAMED is progressing. Following the implementation plan and getting familiar with the information stored in the database’s modules is crucial for economic operators compliance in the EU market.

Read More »
cosmetic products

EU Chemicals Strategy for Sustainability

The Chemicals Strategy for Sustainability (CSS) was recently published by the European Union. The CSS is part of the European Green Deal which aims for a toxic-free environment leading to zero pollution. The initiative proposes a new legislative amend to the EU Cosmetic Products Regulation. Simplification and digitalization of labelling requirements plus review of the definition of nanomaterial are two of the main objectives of the CSS.

Read More »
cosmetic products

Nanotechnology in Sun Care Products

Nanomaterials are increasingly used in cosmetics and personal care products. They are similar to other chemicals/substances, but with specific risks associated to their use. Currently, there are 4 nano-ingredients approved in the European Union for use as UV filters in cosmetic products.

Read More »
cosmetic products

May Butylphenyl Methylpropional be used in Cosmetic Products?

Butylphenyl Methylpropional, also known as Lilial, is a fragrance ingredient that has been used for years in several cosmetic and non-cosmetic products. Nevertheless, some concerns have been expressed regarding the use of this ingredient and its risk to consumers. According to an amendment to the CLP Regulation, the use of Butylphenyl Methylpropional will be prohibited in cosmetic products from 1st March 2022.

Read More »
cosmetic products

How are Cosmetic Products Regulated in the United Arab Emirates?

The United Arab Emirates (UAE) are an emerging market for the beauty industry. Cosmetics and personal care products supplied or sold in the UAE must comply with the health and safety requirements set out in UAE legislation. Overall, the process for importing a cosmetic product into the UAE market from the European Union can be quite straightforward since the UAE has aligned several of its requirements with the European Cosmetic Regulation.

Read More »